CoChat
Sign Up
Cited by 275Tuberculosis Research and EpidemiologyImmune responses and vaccinationsInfectious Diseases and Tuberculosis

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

Open access
Teitelbaum, Rachel, Glatman-Freedman, Aharona, Chen, Bing, Robbins, John B., Unanue, Emil, Casadevall, Arturo, Bloom, Barry R.·1998·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.95.26.15688PMC PMC28105
Open this paper in CoChat — free account

Abstract

Murine mAbs reactive with the surface of Mycobacterium tuberculosis were assayed for their ability to affect the course of infection in mice challenged with virulent organisms. An IgG3 mAb (9d8) specific for arabinomannan and reactive with purified antigen from a clinical isolate of M. tuberculosis conferred partial protection on mice after respiratory challenge (30–60% survival >75 days; P ≤ 0.05). Control mice pretreated with an irrelevant mAb of the same isotype succumbed to tuberculosis within 30 days. Mice with gene disruptions in interferon γ and major histocompatibility complex Class II also were partially protected from challenge. The protective mAb was neither bactericidal nor inhibitory of infection or bacterial replication. Nevertheless, it profoundly altered the nature of the granulomas in the infected lungs. Mice treated with mAb 9d8 and challenged with M. tuberculosis localized the pathogen within granuloma centers, suggesting that the mAb conferred protection by enhancing a cellular immune response.

Integrity signals

Registry

Crossref · 10.1073/pnas.95.26.15688

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It is possible to generate protective mAbs against many viruses and microorganisms.

    “there is ample evidence that it is possible to generate protective mAbs against many viruses and microorganisms (Teitelbaum et al, 1998; Nosanchuk et al, 2003; Both et al, 2013).”

    From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Teitelbaum et al, 1998

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Teitelbaum, R., Glatman-Freedman, A., Chen, B., Robbins, J. B., Unanue, E., Casadevall, A., & Bloom, B. R.
Affiliations
  • National Institutes of Health (US)
  • Howard Hughes Medical Institute and the Department of Microbiology and Immunology of the Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10064; Department of Pediatrics, Jacobi Medical Center, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892; and Department of Pathology, Washington University, St. Louis, MO 63110
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
1998-12-22
Volume
95
Issue
26
Pages
15688-15693
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.95.26.15688
PMC
PMC28105
OpenAlex
W2080781566
Cited by
275
References
39
Citations by year
2026: 5 · 2025: 8 · 2024: 10 · 2023: 14 · 2022: 5 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 11 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 11 · 2013: 13 · 2012: 13
FWCI
6.53
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust
  • National Institutes of Health (5r01hl059842-23, 5r37ai033142-24)
  • National Heart, Lung, and Blood Institute (R01-HL059842)
  • National Institute of Allergy and Infectious Diseases (AI-07118, AI 33142, R01AI007118, R01AI033142, R37-AI033142)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
Keywords
Mycobacterium tuberculosis, monoclonal antibodies, arabinomannan, surface antigens, protective immunity, granuloma formation, interferon-gamma, MHC class II, cell-mediated immunity, respiratory challenge, antibody-mediated protection
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Specificity, Antigens, Bacterial, Antigens, Surface, Female, Genes, MHC Class II, Granuloma, Interferon-gamma, Lung, Mannans, Mice, Inbred BALB C, Mice, Inbred C57BL, Mycobacterium tuberculosis, Neutrophils, Tuberculosis, Virulence, Survival Rate, Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review